Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Biological: trastuzumab
Drug: tipifarnib

First Posted Date: 2004-04-26

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00005842

Locations: 🇺🇸
Institute for Drug Development, San Antonio, Texas, United States
🇺🇸
Brooke Army Medical Center, Fort Sam Houston, Texas, United States

Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors

Phase 1

Completed

Conditions: Liver Neoplasms

First Posted Date: 2004-04-22

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00081848

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: aminocamptothecin

First Posted Date: 2004-04-22

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT00002745

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States
🇺🇸
Cooper Cancer Institute, Camden, New Jersey, United States
🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States

and more 2 locations

Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-04-22

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019357

Locations: 🇺🇸
Medicine Branch, Bethesda, Maryland, United States

Antiviral Therapy in Treating Patients With Kaposi's Sarcoma With or Without HIV Infection

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2004-04-21

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019240

Locations: 🇺🇸
Medicine Branch, Bethesda, Maryland, United States

Flavopiridol in Treating Patients With Refractory Cancer

Phase 1

Completed

Conditions: Lymphoma
Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Small Intestine Cancer

First Posted Date: 2004-04-21

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019344

Locations: 🇺🇸
Medicine Branch, Bethesda, Maryland, United States

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

Phase 2

Terminated

Conditions: Angioimmunoblastic T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Small Lymphocytic Lymphoma
Splenic Marginal Zone Lymphoma
Waldenström Macroglobulinemia

Interventions: Drug: nelarabine

First Posted Date: 2004-04-20

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 111

Registration Number: NCT00005950

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Endostatin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Biological: recombinant human endostatin

First Posted Date: 2004-04-19

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00004229

Locations: 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

506U78 in Treating Patients With Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides/Sezary Syndrome
Small Intestine Lymphoma
Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Stage I Mycosis Fungoides/Sezary Syndrome
Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Stage II Mycosis Fungoides/Sezary Syndrome

Interventions: Drug: nelarabine

First Posted Date: 2004-04-19

Last Posted Date: 2013-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT00005080

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2004-04-13

Last Posted Date: 2013-08-16

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019123

Locations: 🇺🇸
Medicine Branch, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy